The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-invasive Vaccine Market Research Report 2024
Synopsis
Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
Global Non-invasive Vaccine market is projected to reach US$ 3909.1 million in 2029, increasing from US$ 2670 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-invasive Vaccine market research.
The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-invasive Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT
Segment by Type
Oral Vaccine
Nasal Spray Vaccine
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Non-invasive Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
Global Non-invasive Vaccine market is projected to reach US$ 3909.1 million in 2029, increasing from US$ 2670 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-invasive Vaccine market research.
The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-invasive Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT
Segment by Type
Oral Vaccine
Nasal Spray Vaccine
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Non-invasive Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Non-invasive Vaccine Market Overview
1.1 Product Overview and Scope of Non-invasive Vaccine
1.2 Non-invasive Vaccine Segment by Type
1.2.1 Global Non-invasive Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Oral Vaccine
1.2.3 Nasal Spray Vaccine
1.3 Non-invasive Vaccine Segment by Application
1.3.1 Global Non-invasive Vaccine Market Value by Application: (2023-2029)
1.3.2 Public
1.3.3 Private
1.4 Global Non-invasive Vaccine Market Size Estimates and Forecasts
1.4.1 Global Non-invasive Vaccine Revenue 2018-2029
1.4.2 Global Non-invasive Vaccine Sales 2018-2029
1.4.3 Global Non-invasive Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Non-invasive Vaccine Market Competition by Manufacturers
2.1 Global Non-invasive Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Non-invasive Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Non-invasive Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Non-invasive Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Non-invasive Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Non-invasive Vaccine, Product Type & Application
2.7 Non-invasive Vaccine Market Competitive Situation and Trends
2.7.1 Non-invasive Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Non-invasive Vaccine Players Market Share by Revenue
2.7.3 Global Non-invasive Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Non-invasive Vaccine Retrospective Market Scenario by Region
3.1 Global Non-invasive Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Non-invasive Vaccine Global Non-invasive Vaccine Sales by Region: 2018-2029
3.2.1 Global Non-invasive Vaccine Sales by Region: 2018-2023
3.2.2 Global Non-invasive Vaccine Sales by Region: 2024-2029
3.3 Global Non-invasive Vaccine Global Non-invasive Vaccine Revenue by Region: 2018-2029
3.3.1 Global Non-invasive Vaccine Revenue by Region: 2018-2023
3.3.2 Global Non-invasive Vaccine Revenue by Region: 2024-2029
3.4 North America Non-invasive Vaccine Market Facts & Figures by Country
3.4.1 North America Non-invasive Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Non-invasive Vaccine Sales by Country (2018-2029)
3.4.3 North America Non-invasive Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Non-invasive Vaccine Market Facts & Figures by Country
3.5.1 Europe Non-invasive Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Non-invasive Vaccine Sales by Country (2018-2029)
3.5.3 Europe Non-invasive Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Non-invasive Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Non-invasive Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Non-invasive Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Non-invasive Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Non-invasive Vaccine Market Facts & Figures by Country
3.7.1 Latin America Non-invasive Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Non-invasive Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Non-invasive Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Non-invasive Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Non-invasive Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Non-invasive Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Non-invasive Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Non-invasive Vaccine Sales by Type (2018-2029)
4.1.1 Global Non-invasive Vaccine Sales by Type (2018-2023)
4.1.2 Global Non-invasive Vaccine Sales by Type (2024-2029)
4.1.3 Global Non-invasive Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Non-invasive Vaccine Revenue by Type (2018-2029)
4.2.1 Global Non-invasive Vaccine Revenue by Type (2018-2023)
4.2.2 Global Non-invasive Vaccine Revenue by Type (2024-2029)
4.2.3 Global Non-invasive Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Non-invasive Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Non-invasive Vaccine Sales by Application (2018-2029)
5.1.1 Global Non-invasive Vaccine Sales by Application (2018-2023)
5.1.2 Global Non-invasive Vaccine Sales by Application (2024-2029)
5.1.3 Global Non-invasive Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Non-invasive Vaccine Revenue by Application (2018-2029)
5.2.1 Global Non-invasive Vaccine Revenue by Application (2018-2023)
5.2.2 Global Non-invasive Vaccine Revenue by Application (2024-2029)
5.2.3 Global Non-invasive Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Non-invasive Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Non-invasive Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Non-invasive Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Non-invasive Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Lanzhou Institute Non-invasive Vaccine Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Corporation Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Serum Institute Non-invasive Vaccine Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Corporation Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Valneva Non-invasive Vaccine Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.6.1 Shanghai United Cell Corporation Information
6.6.2 Shanghai United Cell Description and Business Overview
6.6.3 Shanghai United Cell Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai United Cell Non-invasive Vaccine Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Corporation Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bibcol Non-invasive Vaccine Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Corporation Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 PaxVax Non-invasive Vaccine Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Corporation Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Vabiotech Non-invasive Vaccine Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Corporation Information
6.11.2 Tiantan Biological Non-invasive Vaccine Description and Business Overview
6.11.3 Tiantan Biological Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Tiantan Biological Non-invasive Vaccine Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Corporation Information
6.12.2 EuBiologics Non-invasive Vaccine Description and Business Overview
6.12.3 EuBiologics Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 EuBiologics Non-invasive Vaccine Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Corporation Information
6.13.2 Panacea Biotec Ltd Non-invasive Vaccine Description and Business Overview
6.13.3 Panacea Biotec Ltd Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Panacea Biotec Ltd Non-invasive Vaccine Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Corporation Information
6.14.2 Bio-Med Non-invasive Vaccine Description and Business Overview
6.14.3 Bio-Med Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bio-Med Non-invasive Vaccine Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
6.15.2 Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Halfkin Bio-Pharmaceuticals Non-invasive Vaccine Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
6.16 AstraZeneca
6.16.1 AstraZeneca Corporation Information
6.16.2 AstraZeneca Non-invasive Vaccine Description and Business Overview
6.16.3 AstraZeneca Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.16.4 AstraZeneca Non-invasive Vaccine Product Portfolio
6.16.5 AstraZeneca Recent Developments/Updates
6.17 Cipla
6.17.1 Cipla Corporation Information
6.17.2 Cipla Non-invasive Vaccine Description and Business Overview
6.17.3 Cipla Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Cipla Non-invasive Vaccine Product Portfolio
6.17.5 Cipla Recent Developments/Updates
6.18 BCHT
6.18.1 BCHT Corporation Information
6.18.2 BCHT Non-invasive Vaccine Description and Business Overview
6.18.3 BCHT Non-invasive Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.18.4 BCHT Non-invasive Vaccine Product Portfolio
6.18.5 BCHT Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Non-invasive Vaccine Industry Chain Analysis
7.2 Non-invasive Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Non-invasive Vaccine Production Mode & Process
7.4 Non-invasive Vaccine Sales and Marketing
7.4.1 Non-invasive Vaccine Sales Channels
7.4.2 Non-invasive Vaccine Distributors
7.5 Non-invasive Vaccine Customers
8 Non-invasive Vaccine Market Dynamics
8.1 Non-invasive Vaccine Industry Trends
8.2 Non-invasive Vaccine Market Drivers
8.3 Non-invasive Vaccine Market Challenges
8.4 Non-invasive Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
